Allarity Therapeutics (NASDAQ:ALLR) and Xilio Therapeutics (NASDAQ:XLO) Financial Contrast

Allarity Therapeutics (NASDAQ:ALLR) and Xilio Therapeutics (NASDAQ:XLO) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, dividends, risk, earnings and valuation.

Insider & Institutional Ownership

11.5% of Allarity Therapeutics shares are held by institutional investors. Comparatively, 54.3% of Xilio Therapeutics shares are held by institutional investors. 0.0% of Allarity Therapeutics shares are held by insiders. Comparatively, 5.2% of Xilio Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares Allarity Therapeutics and Xilio Therapeutics”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Allarity Therapeutics	N/A	N/A	-$11.90 million	N/A	N/A
Xilio Therapeutics	N/A	N/A	-$76.40 million	($1.72)	-0.40

Volatility & Risk

Allarity Therapeutics has a beta of 0.26, indicating that its share price is 74% less volatile than the S&P 500. Comparatively, Xilio Therapeutics has a beta of -0.3, indicating that its share price is 130% less volatile than the S&P 500.

Profitability

This table compares Allarity Therapeutics and Xilio Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Allarity Therapeutics	N/A	-369.67%	-100.06%
Xilio Therapeutics	N/A	-211.50%	-80.31%

Analyst Ratings

This is a summary of recent recommendations and price targets for Allarity Therapeutics and Xilio Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Allarity Therapeutics	0	0	0	0	0.00
Xilio Therapeutics	0	0	1	0	3.00

Xilio Therapeutics has a consensus price target of $4.00, suggesting a potential upside of 475.54%. Given Xilio Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Xilio Therapeutics is more favorable than Allarity Therapeutics.

Summary

Xilio Therapeutics beats Allarity Therapeutics on 7 of the 9 factors compared between the two stocks.

About Allarity Therapeutics

Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. Allarity Therapeutics, Inc. has a collaboration with Detsamma Investments Pty. Ltd. to develop Deflexifol for the treatment of solid tumors. The company was incorporated in 2004 and is headquartered in Boston, Massachusetts.

About Xilio Therapeutics

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company’s checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors. It also develops cytokine programs, which comprises XTX202, a tumor-activated beta-gamma biased IL-2, currently under Phase 2 clinal trials; and XTX301, an investigational tumor-activated, engineered IL-12 molecule, currently under Phase 1 studies. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.